REFERENCES
1. Kim GA, Moon JH, Kim W. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: implication of Janus-faced modernity. Clin Mol Hepatol. 2023;29:831-43.
2. Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919.
3. van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3:100350.
4. Wang X, Xie Q. Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis. J Clin Transl Hepatol. 2022;10:128-33.
5. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
6. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
7. Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Loomba R, Ahmed A. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023. Clin Mol Hepatol. 2025;31:382-93.
8. Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Ahmed A. Trends in mortality from chronic liver disease before, during, and after the COVID-19 pandemic, 2015 to 2023. Ann Intern Med. 2025;178:1054-7.
9. Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Ahmed A. Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States. Clin Mol Hepatol. 2025;31:e268-72.
10. Sohn W, Lee YS, Kim SS, et al; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025. Clin Mol Hepatol. 2025;31:S1-31.
11. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249-53.
12. Koh JH, Ng CH, Nah B, Tan DJH, Loomba R, Huang DQ; Nash HCC Transplant Collaborative. NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2024;22:197-9.e3.
13. Kim D, Manikat R, Wijarnpreecha K, Cholankeril G, Ahmed A. Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018-2023. Clin Mol Hepatol. 2024;30:756-70.
14. Le P, Tatar M, Dasarathy S, et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open. 2025;8:e2454707.
15. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577-86.
16. Baumeister SE, Völzke H, Marschall P, et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology. 2008;134:85-94.
17. Konyn P, Ahmed A, Kim D. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29:S43-57.
18. Danpanichkul P, Suparan K, Prasitsumrit V, Ahmed A, Wijarnpreecha K, Kim D. Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations. Clin Mol Hepatol. 2025;31:74-89.
19. Lindén D, Tesz G, Loomba R. Targeting PNPLA3 to treat MASH and MASH related fibrosis and cirrhosis. Liver Int. 2025;45:e16186.
20. Luo F, Oldoni F, Das A. TM6SF2: a novel genetic player in nonalcoholic fatty liver and cardiovascular disease. Hepatol Commun. 2022;6:448-60.
21. Varadharajan V, Ramachandiran I, Massey WJ, et al. Membrane-bound O-acyltransferase 7 (MBOAT7) shapes lysosomal lipid homeostasis and function to control alcohol-associated liver injury. Elife. 2024;12:RP92243.
22. Mahmood S, Morrice N, Thompson D, et al. Hydroxysteroid 17β-dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high-fat diet obese mice. Exp Physiol. 2025;110:1071-86.
23. Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e76-7.
24. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691-705.
25. Hagström H, Nasr P, Ekstedt M, et al. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver Int. 2019;39:197-204.
26. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-22.
27. Saokaew S, Kanchanasurakit S, Thawichai K, et al. Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: a systematic review and meta-analysis. Medicine. 2021;100:e24557.
28. Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71:1867-75.
29. Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2022;72:372-80.
30. Xu J, Dai L, Zhang Y, et al. Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events. Stroke. 2021;52:103-10.
31. Alon L, Corica B, Raparelli V, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29:938-46.
32. Abosheaishaa H, Hussein M, Ghallab M, et al. Association between non-alcoholic fatty liver disease and coronary artery disease outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2024;18:102938.
33. Gong H, Liu X, Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res. 2021;49:3000605211047074.
34. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:948-63.
35. Jiang F, Chen Q, Wang W, Ling Y, Yan Y, Xia P. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1. J Hepatol. 2020;72:156-66.
36. Badmus OO, Hinds TD Jr, Stec DE. Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease. Curr Hypertens Rep. 2023;25:151-62.
37. Chen X, Chen S, Pang J, et al. Hepatic steatosis aggravates atherosclerosis via small extracellular vesicle-mediated inhibition of cellular cholesterol efflux. J Hepatol. 2023;79:1491-501.
38. Pezzino S, Luca T, Castorina M, Puleo S, Latteri S, Castorina S. Role of perturbated hemostasis in MASLD and its correlation with adipokines. Life. 2024;14:93.
39. Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116-41.
40. Westcott F, Dearlove DJ, Hodson L. Hepatic fatty acid and glucose handling in metabolic disease: potential impact on cardiovascular disease risk. Atherosclerosis. 2024;394:117237.
41. Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020;42:101092.
42. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835.
43. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528-62.
44. Mellemkjær A, Kjær MB, Haldrup D, Grønbæk H, Thomsen KL. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease. Eur J Intern Med. 2024;122:28-34.
45. Correia LCL. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;379:1387.
46. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr. 2010;92:1189-96.
47. Kawaguchi T, Charlton M, Kawaguchi A, et al. Effects of Mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials. Semin Liver Dis. 2021;41:225-34.
48. Haigh L, Kirk C, El Gendy K, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Clin Nutr. 2022;41:1913-31.
49. Kim D, Murag S, Cholankeril G, et al. Physical activity, measured objectively, is associated with lower mortality in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2021;19:1240-7.e5.
50. Tsunoda K, Kitano N, Kai Y, Jindo T, Uchida K, Arao T. Dose-response relationships of accelerometer-measured sedentary behaviour and physical activity with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54:1330-9.
51. van Kleef LA, Hofman A, Voortman T, de Knegt RJ. Objectively measured physical activity is inversely associated with nonalcoholic fatty liver disease: the rotterdam study. Am J Gastroenterol. 2022;117:311-8.
52. Franco I, Bianco A, Mirizzi A, et al. Physical activity and low glycemic index Mediterranean diet: main and modification effects on NAFLD score. Results from a randomized clinical trial. Nutrients. 2020;13:66.
53. Abdelbasset WK, Tantawy SA, Kamel DM, Alqahtani BA, Soliman GS. A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease. Medicine. 2019;98:e14918.
54. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
55. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44.
56. Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.
57. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679-90.
58. Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:367-78.
59. Majzoub AM, Nayfeh T, Barnard A, et al. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther. 2021;54:880-9.
60. Francque SM, Bedossa P, Ratziu V, et al; NATIVE Study Group. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547-58.
61. Thomson MJ, Serper M, Khungar V, et al. Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH study. Clin Gastroenterol Hepatol. 2022;20:458-60.e4.
62. Shahab O, Biswas R, Paik J, Bush H, Golabi P, Younossi ZM. Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality. Hepatol Commun. 2018;2:1227-34.
63. Athyros VG, Tziomalos K, Gossios TD, et al; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916-22.
64. Ayada I, van Kleef LA, Zhang H, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023;87:104392.
65. Kaplan DE, Serper MA, Mehta R, et al; VOCAL Study Group. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology. 2019;156:1693-706.e12.
66. Zhou X, Yu J, Li L, et al. Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis. Obes Surg. 2016;26:2590-601.
67. Kwok CS, Pradhan A, Khan MA, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol. 2014;173:20-8.
68. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159:1290-301.e5.
69. Sakai K, Okamura T, Toyokuni E, et al. Metabolic dysfunction-associated steatotic liver disease: a superior predictor for incident type 2 diabetes over traditional criteria - NAGALA study. J Diabetes Investig. 2024;15:1788-96.
70. Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41:372-82.
71. Björkström K, Stål P, Hultcrantz R, Hagström H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017;15:1461-8.
72. Kim D, Loomba R, Ahmed A. Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017-2023. Clin Mol Hepatol. 2025;31:e235-8.
73. Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793-801.
74. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335-47.
75. Younossi ZM, Golabi P, Price JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22:1999-2010.e8.
76. Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78:471-8.
77. Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol. 2021;2021:6613827.
78. Sabatini S, Sen P, Carli F, et al. Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis. Cell Rep Med. 2024;5:101820.
79. Pal SC, Méndez-Sánchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. World J Gastroenterol. 2023;29:3999-4008.
80. Zhang C, Sui Y, Liu S, Yang M. Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Explor Dig Dis. 2023;2:246-75.
81. Yu L, Gao F, Li Y, et al. Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications. Biomed Pharmacother. 2024;175:116724.
82. Ding Z, Wei Y, Peng J, Wang S, Chen G, Sun J. The potential role of C-reactive protein in metabolic-dysfunction-associated fatty liver disease and aging. Biomedicines. 2023;11:2711.
83. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-75.
84. Drummen M, Dorenbos E, Vreugdenhil ACE, et al. Long-term effects of increased protein intake after weight loss on intrahepatic lipid content and implications for insulin sensitivity: a PREVIEW study. Am J Physiol Endocrinol Metab. 2018;315:E885-91.
85. Skytte MJ, Samkani A, Petersen AD, et al. A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. Diabetologia. 2019;62:2066-78.
86. Cho Y-E, Kim D-K, Seo W, Gao B, Yoo S-H, Song B-J. Fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450-2E1-mediated oxidative and nitrative stress. Hepatology. 2021;73:2180-95.
87. Souza Cruz EM, de Morais Juliana M, Dalto da Rosa CVi, et al. Long-term sucrose solution consumption causes metabolic alterations and affects hepatic oxidative stress in Wistar rats. Biol Open. 2020;9:bio047282.
88. Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24:2083-94.
89. Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: insights from the cellular to patient levels. Gut Liver. 2021;15:827-40.
90. Diabetes A. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2018. Diabetes Care. 2018;41:S73-85.
91. Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications. 2007;21:137-42.
92. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305-15.
93. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177:633-40.
94. Ratziu V, Giral P, Jacqueminet S, et al; LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology. 2008;135:100-10.
95. He Y, Ao N, Yang J, Wang X, Jin S, Du J. The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy. Ann Hepatol. 2020;19:44-52.
96. Bizino MB, Jazet IM, de Heer P, et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia. 2020;63:65-74.
97. Eguchi Y, Kitajima Y, Hyogo H, et al; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45:269-78.
98. Petit JM, Cercueil JP, Loffroy R, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study. J Clin Endocrinol Metab. 2017;102:407-15.
99. Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43:1352-5.
100. Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10:393-406.
101. Sanyal AJ, Newsome PN, Kliers I, et al; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
102. Akuta N, Kawamura Y, Watanabe C, et al. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res. 2019;49:531-9.
103. Seko Y, Sumida Y, Tanaka S, et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017;47:1072-8.
104. Gautam A, Agrawal PK, Doneria J, Nigam A. Effects of canagliflozin on abnormal liver function tests in patients of type 2 diabetes with non-alcoholic fatty liver disease. J Assoc Physicians India. 2018;66:62-6.
105. Lai L-L, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan W-K. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci. 2020;65:623-31.
106. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41:1801-8.
107. Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61:1923-34.
108. Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21:285-92.
109. Bharatselvam S, Schwenger KJP, Ghorbani Y, et al. Assessing clinical and metabolic responses related to hyperlipidemia, MASLD and type 2 diabetes: sleeve versus RYGB. Nutrition. 2024;126:112530.
110. Wyne KL, Nair L, Schneiderman CP, et al. Hypothyroidism prevalence in the United States: a retrospective study combining national health and nutrition examination survey and claims data, 2009-2019. J Endocr Soc. 2022;7:bvac172.
111. Mantovani A, Csermely A, Bilson J, et al. Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis. Gut. 2024;73:1554-61.
112. Kim D, Vazquez-Montesino LM, Escober JA, et al. Low thyroid function in nonalcoholic fatty liver disease is an independent predictor of all-cause and cardiovascular mortality. Am J Gastroenterol. 2020;115:1496-504.
113. Ritter MJ, Amano I, Hollenberg AN. Thyroid hormone signaling and the liver. Hepatology. 2020;72:742-52.
114. Yan F, Wang Q, Lu M, et al. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity. J Hepatol. 2014;61:1358-64.
115. Bao S, Li F, Duan L, Li J, Jiang X. Thyroid-stimulating hormone may participate in insulin resistance by activating toll-like receptor 4 in liver tissues of subclinical hypothyroid rats. Mol Biol Rep. 2023;50:10637-50.
116. Kizivat T, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and nonalcoholic fatty liver disease: pathophysiological associations and therapeutic implications. J Clin Transl Hepatol. 2020;8:347-53.
117. Liu Y, Wang W, Yu X, Qi X. Thyroid function and risk of non-alcoholic fatty liver disease in euthyroid subjects. Ann Hepatol. 2018;17:779-88.
118. Liu L, Yu Y, Zhao M, et al. Benefits of levothyroxine replacement therapy on nonalcoholic fatty liver disease in subclinical hypothyroidism patients. Int J Endocrinol. 2017;2017:5753039.
119. Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012-24.
120. Harrison SA, Bedossa P, Guy CD, et al; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
121. Manzano-Nunez R, Santana-Dominguez M, Rivera-Esteban J, et al. Non-alcoholic fatty liver disease in patients with polycystic ovary syndrome: a systematic review, meta-analysis, and meta-regression. J Clin Med. 2023;12:856.
122. Shengir M, Chen T, Guadagno E, et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: a systematic review and meta-analysis. JGH Open. 2021;5:434-45.
123. Kumarendran B, O’Reilly MW, Manolopoulos KN, et al. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database. PLoS Med. 2018;15:e1002542.
124. Andrisse S, Childress S, Ma Y, et al. Low-dose dihydrotestosterone drives metabolic dysfunction via cytosolic and nuclear hepatic androgen receptor mechanisms. Endocrinology. 2017;158:531-44.
125. Zhang Y, Meng F, Sun X, et al. Hyperandrogenism and insulin resistance contribute to hepatic steatosis and inflammation in female rat liver. Oncotarget. 2018;9:18180-97.
126. Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol. 2014;20:14172-84.
128. Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015;21:560-74.
129. Austregésilo de Athayde De Hollanda Morais B, Martins Prizão V, de Moura de Souza M, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complications. 2024;38:108834.
130. Chane E, Wondifraw H, Hadgu R, Fasil A. Assessment of liver function tests of women taking hormonal contraceptives at University of Gondar comprehensive specialized hospital and Family Guidance Association of Gondar (FGAE), 2022; a comparative cross-sectional study. PLoS One. 2023;18:e0289746.
133. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156-62.
134. Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int. 2019;39:342-52.
136. Hashim A, Maraey A, Elzanaty A, et al. Nonalcoholic fatty liver disease predicts acute kidney injury readmission in heart failure hospitalizations: a nationwide analysis. Curr Probl Cardiol. 2023;48:101816.
137. Bansal A, Chonchol M. Metabolic dysfunction-associated kidney disease: pathogenesis and clinical manifestations. Kidney Int. 2025;108:194-200.
138. Zhen J, Zhou Z, He M, et al. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front Endocrinol. 2023;14:1085041.
139. Castillo-Rodriguez E, Fernandez-Prado R, Esteras R, et al. Impact of altered intestinal microbiota on chronic kidney disease progression. Toxins. 2018;10:300.
140. Abbate M, Mascaró CM, Montemayor S, et al. Energy expenditure improved risk factors associated with renal function loss in NAFLD and mets patients. Nutrients. 2021;13:629.
141. Truong E, Noureddin M. The interplay between nonalcoholic fatty liver disease and kidney disease. Clin Liver Dis. 2022;26:213-27.
142. Sumida Y, Yoneda M, Toyoda H, et al. Common drug pipelines for the treatment of diabetic nephropathy and hepatopathy: can we kill two birds with one stone? Int J Mol Sci. 2020;21:4939.
143. Skov J, Dejgaard A, Frøkiær J, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013;98:E664-71.
144. Mima A. Sodium-glucose cotransporter 2 inhibitors in patients with non-diabetic chronic kidney disease. Adv Ther. 2021;38:2201-12.
145. Ruan Z, Lu T, Chen Y, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol. 2022;158:745-53.
146. Untaaveesup S, Kantagowit P, Ungprasert P, et al. The risk of metabolic dysfunction-associated steatotic liver disease in moderate-to-severe psoriasis: a systematic review and meta-analysis. J Clin Med. 2025;14:1374.
147. Romero-Pérez D, Belinchón-Romero I, Bellot P, Francés R, Marco F, Ramos-Rincón JM. Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk. Australas J Dermatol. 2019;60:e304-10.
148. Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci. 2016;17:217.
149. Costache DO, Blejan H, Cojocaru DL, et al. Intersecting pathways: nonalcoholic fatty liver disease and psoriasis duet-A comprehensive review. Int J Mol Sci. 2024;25:2660.
150. Aryanian Z, Asghari M, Zanousi PP, Ghadimi R, Kebria AS, Hatami P. Adherence to the Mediterranean diet in patients with psoriasis and its relationship with the severity of the disease: a case-control study. Health Sci Rep. 2024;7:e70049.
151. Sualeheen A, Tan SY, Georgousopoulou E, et al. Mediterranean diet for the management of metabolic dysfunction-associated steatotic liver disease in non-Mediterranean, Western countries: What’s known and what’s needed? Nutr Bull. 2024;49:444-62.
152. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30:282-7.
153. Silva FS, Ribeiro MP, Santos MS, Rocha-Pereira P, Santos-Silva A, Custódio JB. Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity. Toxicology. 2013;306:93-100.
154. Krefting F, Scheib C, Benson S, et al. Baseline pathological liver function tests in patients with psoriasis support the indication for systemic therapy rather than being a reason against it: a real-world analysis. Psoriasis. 2025;15:29-44.
155. Jia X, Zou C, Lu N, Lu Q, Xie C. Obstructive sleep apnea is ralated to metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus. Sci Rep. 2025;15:24627.
156. Aron-Wisnewsky J, Clement K, Pépin JL. Nonalcoholic fatty liver disease and obstructive sleep apnea. Metabolism. 2016;65:1124-35.
157. Miao L, Yang L, Guo LS, et al. Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2022;10:230-7.
158. Feng T, Li J, Wu L, He X, Ye J. Association between metabolic dysfunction-associated steatotic liver disease and pulmonary function: a population-based and two-sample mendelian randomization study. BMC Pulm Med. 2024;24:368.
159. Abdelhameed F, Mustafa A, Kite C, et al. Gut microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD): emerging pathogenic mechanisms and therapeutic implications. Livers. 2025;5:11.
160. Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25:1054-62.e5.
161. Martínez-Domínguez SJ, García-Mateo S, Gargallo-Puyuelo CJ, et al. Inflammatory bowel disease is an independent risk factor for metabolic dysfunction-associated steatotic liver disease in lean individuals. Inflamm Bowel Dis. 2024;30:1274-83.
162. Yao J, Sun J, Ebrahimi F, et al. Long-term risk of chronic liver disease in patients with celiac disease: a nationwide population-based, sibling-controlled cohort study. Lancet Reg Health Eur. 2025;50:101201.
163. Wu S, Yuan C, Yang Z, et al. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. BMC Med. 2022;20:262.
164. Sartini A, Gitto S, Bianchini M, et al. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 2018;9:87.
165. Wei Z, Wang J. Exploration of the core pathway of inflammatory bowel disease complicated with metabolic fatty liver and two-sample Mendelian randomization study of the causal relationships behind the disease. Front Immunol. 2024;15:1375654.
166. Ng JJJ, Loo WM, Siah KTH. Associations between irritable bowel syndrome and non-alcoholic fatty liver disease: a systematic review. World J Hepatol. 2023;15:925-38.
167. Lee HJ, Lee DC, Kim CO. Association between 10-year fracture probability and nonalcoholic fatty liver disease with or without sarcopenia in Korean men: a nationwide population-based cross-sectional study. Front Endocrinol. 2021;12:599339.
168. Han E, Lee YH, Kim YD, et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am J Gastroenterol. 2020;115:584-95.
169. Li X, He J, Sun Q. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Clin Nutr. 2024;43:2005-16.
170. Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;45:510-8.
171. Wong R, Yuan LY. Sarcopenia and metabolic dysfunction associated steatotic liver disease: time to address both. World J Hepatol. 2024;16:871-7.
172. Stefan N, Schick F, Birkenfeld AL, Häring HU, White MF. The role of hepatokines in NAFLD. Cell Metab. 2023;35:236-52.
173. Kim MJ, Cho YK, Kim EH, et al. Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography. J Cachexia Sarcopenia Muscle. 2024;15:1942-52.
174. Zhou BG, Jiang X, She Q, Ding YB. Association of MASLD with the risk of extrahepatic cancers: a systematic review and meta-analysis of 18 cohort studies. Eur J Clin Invest. 2024;54:e14276.
175. Kim GA, Lee HC, Choe J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2017;68:140-6.
176. Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study. J Hepatol. 2019;71:1229-36.
177. Kim D, Adejumo AC, Yoo ER, et al. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. Gastroenterology. 2019;157:1055-66.e11.
179. Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 2021;45:622.
180. Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20:40-54.
181. Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018;15:671-82.
182. Tai J, Hsu CW, Chen WT, et al. Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype. Cancer Sci. 2024;115:564-74.
183. Longo M, Meroni M, Paolini E, et al. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. Cell Mol Gastroenterol Hepatol. 2022;13:759-88.
184. Medina-Julio D, Ramírez-Mejía MM, Cordova-Gallardo J, Peniche-Luna E, Cantú-Brito C, Mendez-Sanchez N. From liver to brain: how MAFLD/MASLD impacts cognitive function. Med Sci Monit. 2024;30:e943417.
